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1. Introduction 
To be effective an active drug or principle must cross the stratum corneum barrier; this 
process can be influenced to obtain better functional and therapeutical effects. In spite of 
the wide variety of the methods studied in order to improve the transdermal transfer to 
obtain systemic effects, the applicability is limited in this field. Attention to the epidermal 
barrier and penetration of active principles has been reported mostly in studies 
concerning dermocosmetics. Studies regarding methods of penetration are gaining 
experimental and clinical interest. Cutaneous bioavailability of most commercially 
available dermatological formulations is low. Increase of intradermal delivery can relate 
to chemical, biochemical, or physical manipulations. Chemical enhancers have been 
adopted to: (a) increase the diffusibility of the substance across the barrier, (b) increase 
product solubility in the vehicle, (c) improve the partition coefficient. Moreover, methods 
of interference with the biosynthesis of some lipids allow the modification of the structure 
of the barrier to increase the penetration. Recent development of these methods are here 
reported and underline the importance and role of vehicles and other factors that 
determine effects of partition and diffusion, crucial to absorption of high molecular 
weight haptens in allergic contact dermatitis. 
The skin represents an important barrier of the penetration of exogenous substances into the 
body and, on the other hand, a potential avenue for the transport of functional active 
principles into the skin and/or the body. Several studies have shown the modalities through 
which these molecules cross the horny layer, which represents the most important limiting 
factor of the process of diffusion and penetration, and have discussed how to increase the 
penetration of pharmacologically active substances [1-3]. The stratum corneum has a very 
peculiar structure: the corneocytes (the bricks: about 85% of the mass of horny mass) and 
intercellular lipids (15%) are arranged in approximately 15-20 layers. It consists of about 70 
% proteins, 15 % lipids, and only 15 % water. In the corneocytes contain keratin, filagrin, 
and demolition products [4]. The corneocyte lacks lipids, but is rich in proteins. The lipids 
are inside extracellular spaces, in a bilayer organization surrounding corneocytes. The very 
low permeability of the horny layer to hydrosoluble substances is because of this 
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extracellular lipid matrix. Cutaneous penetration of hydrophilic substances is limited 
because of the convoluted and tortuous intercellular space and hydrophobicity of three 
lipidic constituents: ceramides, cholesterol, and free fatty acids that are present in the molar 
ratio: 1: 1: 1 (weight ratio: ceramides 50%, cholesterol 35-40%, free fatty acids 10-15%) [5]. 
This ratio is critical: because the diminution of the concentration of one of these types of 
lipids alters the molar ratio functional to the normality of the barrier and modifies its 
integrity [6]. The variations of this lamellar structure and/or its lipid composition are the 
structural and biochemical basis of permeability variations along with the thickness of the 
horny layer. The extracellular matrix forms also the so-called the ‘horny layer reservoir’ 
(some substances are partially retained in the corneous layer and are slowly released) [7-8]. 
Various processes carried out serially or in parallel, are involved in cutaneous penetration of 
substances and these may cross the stratum corneum via an intercellular or a transcellular 
route. Moreover, entrance through pilosebaceous units and eccrine glands is possible. 
Many efforts to obtain therapeutic effects in tissues far from the skin have been made. We 
may have: topical administration, with a pharmacological effect limited to skin, with some 
unavoidable systemic absorption; loco-regional delivery, when the therapeutic effect is 
obtained in tissues more or less deeply beneath the skin (muscles, articulations, vessels, 
etc.) with limited systemic absorption; and transdermic delivery that aims to obtain, 
through application of preparations on the skin, pharmacologically active levels for the 
treatment of systemic diseases through skin vascular network or for the diagnosis of a 
suspected contact dermatitis. 
1.1 Stratum corneum barrier and intradermal delivery 
The penetration through the stratum corneum involves partition phenomena of applied 
molecules between lipophilic and hydrophilic compartments. For many substances the 
penetration takes place through an intercellular way, more than transcellular, diffusing 
around the keratinocytes. 
Intercellular movement. The lipid lamellae (each one including 2 or 3 bilayers and made 
mainly of ceramides, cholesterol, and free fatty acids) are the intercellular structure of the 
horny layer, with the main role in barrier function. Most solute substances, non-polar or 
polar, penetrate across intercellular lipid avenues. The permeability of very polar solutes is 
constant and similar to the transport of ions (e.g. potassium ions). Lipophilic solute 
permeability increases according to specific lipophilic properties. 
Transcellular movement. Stratum corneum intracellular components are essentially devoid 
of lipids and lack a functional lipid matrix around keratin and keratohyalin. This results in 
an almost impenetrability of corneocytes [9]. Degradation of the corneodesmosomes causes 
formation of a continuous lacunar dominio ("aqueous pore") allowing intercellular 
penetration; the lacunae formed are scattered and not continuous, and form as a result of 
occlusion, ionophoresis, and ultrasound waves. These may become larger and connect 
forming a net ("pore-way"). Various methods can induce this type of permeability increase : 
physical and chemical methods [10]. 
Transport through follicular and gland structures. Movement through hair follicles, 
pilosebaceous units, and eccrine glands is limited. The orifices of the pilosebaceous units 
represent about 10 percent of all skin delivery in areas where their density is high (face 
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and scalp) and only 0.1 percent in areas where their density is low. This is a possible 
selective way for some drugs. Follicular penetration may be influenced by sebaceous 
secretion, which favors the absorption of substances soluble in lipids. The penetration 
through the pilosebaceous units is dependent upon the property of the substance and 
type of preparation. 
2. Role of the vehicle and excipients and interaction with the active principles 
A vehicle is defined by the type of preparation (cream, ointment, gel) and the excipients 
(water, paraffin, propilen glycol); the terms "vehicle" and "excipient" refer to different 
entities. 
Vehicle and excipients deeply influence the velocity and magnitude of absorption and 
consequently the bioavailability and efficacy. The excipients of the vehicle modulate the 
effects of partition and diffusion in the stratum corneum. 
A lipid preparation that promotes occlusion may enhance the penetration of the drug, but 
ointments and lipid preparations are not always more powerful than creams. Creams, gels 
and solutions may be formulated so as to obtain an effect equivalent to that of ointments. 
Topical corticosteroids of different classes of potency may show the same activity when 
formulated in different vehicles. A gel preparation of kellin, obtaining better penetration, 
has demonstrated important results in the treatment of vitiligo. Also transfollicular 
penetration is influenced by vehicle and excipients; better results are given by lipophilic 
and alcoholic vehicles. Relevant factors include dimension and charge of the molecules of 
the solute. 
3. Pharmacokinetic parameters - Vehicle/ corneous layer partition 
For the purpose of the study of the mechanisms of transport and the functions of the skin 
barrier, it can be considered as a membrane or a cluster of membranes (mathematical 
principles can be applied) [11]. On the whole, transport through the horny layer is mainly a 
molecular passive diffusion. The physico-chemical and structural properties of the 
substance determine the capacity of diffusion and penetration through the membrane: 
important determinants are solubility and diffusibility. 
The diffusibility and the ability of a solute to penetrate through the barrier is influenced by 
several factors including the tortuosity of the intercellular route. This passive process of 
absorption follows Fick's law of diffusion: the velocity of absorption - flow - is proportional 
to the difference of concentration of the substance in relation to that within the barrier. It can 
finally be noted that the permeability coefficient relates flow and concentration, resulting 
from partition coefficient, diffusion coefficient, and length of diffusion route [12-16]. 
4. Conditions that modify the barrier function 
During hydration the greater part of the water is associated with intracellular keratin; the 
natural factor of hydration or natural moisturizing factor (NMF) absorbs a noticeable 
amount of water (10% of the weight of the corneocyte). Corneocytes swell and the barrier 
properties of the stratum corneum are deeply altered. In the intercellular space the small 
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amount of water linked to polar groups by hydration does not alter the organization of 
lipids and does not reduce of permeability [17]. The effect of the hydration however has a 
discontinuous effect; the increase in permeability may be by ten times for some substances 
and very limited for others [18]. Occlusion partially hinders the loss of humidity of the skin, 
increasing the content of water of the horny layer. However the NMF level in the horny 
layer is almost zero. It seems therefore that there is a homeostatic mechanism that prevents 
hyperhydration of the skin [9]. Occlusion may increase the absorption by several times, 
especially for hydrophilic compounds. However, in some conditions it may promote the 
formation of a reservoir effect. The acidity of the cutaneous surface, controlling homeostasis 
and enzymatic activities, influences permeability [19]; the metabolic activity of the skin 
(enzymatic oxidoreductive processes) may modify the substances applied, influencing 
permeability and effects. 
Absorption is also influenced by other skin properties that vary at different cutaneous 
anatomical sites. For instance, the absorption diminishes greatly as one moves from the 
palpebral skin to the plantar surfaces [20]. 
Age influences skin absorption. Various biological activities are lower in the skin of the aged 
individual. Great variation is also noted for the premature infant and neonate, who have 
greater cutaneous permeability [21]. There are no experimental data confirming the validity 
of friction on transcutaneous absorption [6]. Alterations of the barrier induce modifications 
of TEWL [9]. In addition, the horny layer may be defined as a biosensor; alterations of 
external humidity regulate proteolysis of filaggrin, synthesis of lipids, DNA, and proteins 
within keratinocytes, which can lead also to inflammatory phenomena [22]. 
The cutaneous bioavailability of most commercial dermatological formulations IS about  
1-5% of applied dose [23]. 
The active substances of topical formulations are generally absorbed in small quantities; 
only a reduced fraction passes from the vehicle into the stratum corneum. The greater part 
remains on the surface of the skin, subject to loss in several ways such as by sweating, 
chemical degradation, and removal. Future standards would therefore aim to make 
formulations not merely high in concentration, but pharmaceutically optimized to have an 
elevated (50-100%) bioavailability. On the other hand, one must consider the marked 
variations of the different cutaneous areas and skin conditions that make uncertain the 
therapeutic equivalence when compared with other ways of administration in clinical 
conditions [24].  
5. Methods of modulation of cutaneous permeability 
When a substance is applied on the skin with a simple vehicle the therapeutic result can be 
unsatisfactory because of the insufficient concentration obtained in the application area [25]. 
In the last few years strategies have been developed in order to increase the efficacy of the 
vehicle [26]. They may be of chemical, biochemical or physical order. 
5.1 Chemical enhancers 
In order to increase the penetration the vehicle may be integrated with enhancers that by 
interacting with intercellular lipids improve the diffusion coefficient of the substance in the 
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stratum corneum. Chemical enhancers may: a) increase the diffusibility of the substance 
inside the barrier, b) increase the solubility in the vehicle or both, or c) improve the partition 
coefficient. 
These substances may frequently have a not specific action. Enhancers of this type, that 
are not widely used, are Azone, Dermac SR-38, and oleic acid [27]. In some cases, 
however, these have an irritating effect and must be carefully evaluated in the various 
preparations [28]. 
Excipients like ethanol, propylene-glycol, and dimethylsulfoxide (DMSO) may increase the 
diffusion by altering the organization of lipids of the horny layer [29]. The interference with 
the biosynthesis of some lipids may alter the structure of the barrier and increase the 
penetration. Methods have also been studied that interfere with secretion and organization 
of lipids (e.g., brefeldine, monetine, and cloroquine). In addition, enhancers that alter the 
supramolecolar organization of the bistratified lamellae (synthetic analogs of fats, inducing 
abnormalities of the organization of the membranes; complex precursors that can not be 
metabolized, etc.) have been studied. These methods produce an alteration of the critical 
molar ratio among ceramides, cholesterol, and fatty acids; if there is decrease or excess of 
one of these 3 key lipids, the lamellar organization cannot be maintained. There may be 
separation of the phases with more permeable interestitial spaces and formation of a new 
way of penetration [30]. 
The efficacy of the enhancers may be increased by inhibition of the metabolic reaction of 
repair once the alteration of the barrier has been obtained. This would involve inhibiting 
metabolic sequences that can rebuild and maintain the barrier function. Inhibitors of 
enzymes with relevant functions (e.g., lovastatin) or specific inhibitors of enzymes 
synthesizing ceramides or fatty acids induces alteration of the molar ratio of the three 
critical lipids and leads to discontinuity in the lamellar layer system [31]. Other 
enhancements may be obtained by modifying the polarity [32]. 
The number of drugs for which transdermic methods for systemic use has been possible is 
very small and restricted to lipophilic and low molecular weight substances (e.g. nicotinic 
acid, nitroglycerin, clonidine, steroid hormones, and scopolamine) [33]. 
5.2 Carrier vesicular systems 
Liposome formulations can be very effective. However, they probably increase penetration 
only through the transappendigeal avenue [34]. Niosomes and transferosomes, formed by 
modified liposomes (phosphatidilcoline, sodium cholate, ethanol), are systems based on the 
ability of vesicles to cross the unaltered horny layer because of the osmotic gradient between 
external and internal layers of the barrier. These are "flexible" vesicles able to transport their 
contents through the intercellular tortuous route of the corneous layer. 
5.3 Scratch-patch test 
Although closed patch tests are the mainstay for the evaluation of allergic contact 
dermatitis, occasionally, even when appropriate concentrations of allergens are used and 
contact allergy is strongly suspected, positive reactions are not always obtained. As in the 
cases that will be described patch test with high molecular weight substances as heparin, 
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or low molecular weight as acyclovir may give doubtful results in sensitized patients, 
possibly due to poor penetration of this substances through the epidermis.  Scratch–patch 
testing, by compromising epidermal barrier function, enables enhanced penetration of 
substances into the skin [35-37]. The method is performed by causing mechanical injury to 
the epidermis with a sterile skin prick lancet in order to compromise the stratum 
corneum, which represents the most important barrier limiting hapten penetration. The 
test reactions are usually read after D2 and D3, when possible, also after D4 and D7. The 
method of grading a positive scratch–patch test is identical to that used for conventional 
patch testing with no differences. It can be used for many drugs: low molecular wheight 
molecules (e.g. β-blockers, antiviral drugs etc.) and also high molecular wheight 
molecules (e.g. heparin etc.): 
5.3.1 β-blockers 
Contact allergy to topical β-blockers is a well-recognized side-effect of glaucoma treatment 
[38-41]. Sensitization may be singly to agents such as timolol, befunolol, levobunolol, or, 
more rarely, to multiple β-blockers in a single patient.  
A closed patch test, usually used in clinical practice for the diagnosis of allergic contact 
dermatitis, is often sufficient to show β-blockers contact allergy. However, there may be 
difficulties in obtaining positive patch tests to β-blockers, as showed in earlier reports [42-
43]. Poor penetration through intact skin on the back, where patch testing is normally 
applied, may be a factor.  
5.3.2 Antiviral drugs  
Topical antiviral drugs are frequently used, but although repeated applications can lead to 
contact reactions [44-45], adverse cutaneous reactions are not commonly observed. Allergic 
contact dermatitis caused by acyclovir is rare, with only 20 studies reported [46-48]. Because 
of the doubtful reactions with antiviral, especially acyclovir, and in view of the suggestive 
clinical history, we recommend the scratch–patch test followed by repeated open 
application test (ROAT). 
5.3.3 Heparin 
Heparin is a sulfated glycosaminoglycan with anticoagulant properties. It is usually injected 
intravenously or subcutaneously but is also available for topical application. Cutaneous 
allergic reactions due to subcutaneously injected heparin have been reported [49-50].  
We report a case of patch-test-negative allergic contact dermatitis, diagnosed by scratch 
patch testing, from a gel containing heparin. Allergic reaction to subcutaneously injected 
heparins is not a rare occurrence [51-52] but there are only a few reports of contact 
dermatitis from topical heparin [53]. 
In cases of suspected contact allergy, when conventional closed patch test shows negative 
or doubtful results, scratch–patch testing should be considered. We recommend, after 
performing scratch-patch test, to execute a ROAT  to be sure the drug can be applied 
safely.  
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